Search Results - "Olurinde, Mobolaji"

S1052 Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study by Panaccione, Remo, Hart, Ailsa, Steinwurz, Flavio, Danese, Silvio, Hisamatsu, Tadakazu, Cao, Qian, Olurinde, Mobolaji, Vetter, Marion, Yang, Zijiang, Wang, Yuhua, Johanns, Jewel, Terry, Natalie A., Sands, Bruce E., D'Haens, Geert R.

Get full text

Potent Neutralization of Severe Acute Respiratory Syndrome (SARS) Coronavirus by a Human mAb to S1 Protein That Blocks Receptor Association by Sui, Jianhua, Li, Wenhui, Murakami, Akikazu, Tamin, Azaibi, Matthews, Leslie J., Wong, Swee Kee, Moore, Michael J., Aimee St. Clair Tallarico, Olurinde, Mobolaji, Choe, Hyeryun, Anderson, Larry J., Bellini, William J., Farzan, Michael, Marasco, Wayne A., Lamb, Robert A.

“…Effective prophylaxis and antiviral therapies are urgently needed in the event of reemergence of the highly contagious and often fatal severe acute respiratory…”
Get full text

Association between alendronate, serum alkaline phosphatase level, and heterotopic ossification in individuals with spinal cord injury by Ploumis, Avraam, Donovan, Jayne M., Olurinde, Mobolaji O., Clark, Dana M., Wu, Jason C., Sohn, Douglas J., O'Connor, Kevin C.

“…Context/objective Only sparse evidence exists regarding the effectiveness of oral alendronate (ALN) in the prevention of heterotopic ossification (HO) in…”
Get full text

Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent by Olurinde, Mobolaji O, Shen, Ching-Hung, Drake, Adam, Bai, Ailin, Chen, Jianzhu

“…How tumor-infiltrating lymphocytes (TILs) that are tumor-specific but functionally tolerant persist in the antigen-expressing tumor tissue is largely unknown…”
Get full text

COVALENT BINDING OF 2-PHENYLPROPIONYL-S-ACYL-COA THIOESTER TO TISSUE PROTEINS IN VITRO by LI, Chunze, OLURINDE, Mobolaji O, HODGES, Laura M, GRILLO, Mark P, BENET, Leslie Z

“…In this study, we investigated the possible involvement of acyl-CoA, reactive intermediary metabolites of 2-arylpropionic acids (profens), in protein adduct…”
Get full text

25696 Impact of guselkumab on quality of life and work productivity outcomes among patients with moderate-to severe plaque psoriasis in the Corrona Psoriasis Registry by Armstrong, April W., Callis-Duffin, Kristina, Fitzgerald, Timothy, Teeple, Amanda, Uy, Jonathan, Olurinde, Mobolaji, Rowland, Katelyn, McLean, Robert R., Guo, Lin, Shan, Ying, Van Voorhees, Abby S.

Get full text

26916 Effectiveness of guselkumab among patients with moderate-to-severe plaque psoriasis in the Corrona Psoriasis Registry by Armstrong, April W., Callis-Duffin, Kristina, Fitzgerald, Timothy, Teeple, Amanda, Uy, Jonathan, Olurinde, Mobolaji, Rowland, Katelyn, McLean, Robert R., Guo, Lin, Shan, Ying, Van Voorhees, Abby S.

Get full text

The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction by Berger, Miles, Oyeyemi, Deborah, Olurinde, Mobolaji O., Whitson, Heather E., Weinhold, Kent J., Woldorff, Marty G., Lipsitz, Lewis A., Moretti, Eugene, Giattino, Charles M., Roberts, Kenneth C., Zhou, Junhong, Bunning, Thomas, Ferrandino, Michael, Scheri, Randall P., Cooter, Mary, Chan, Cliburn, Cabeza, Roberto, Browndyke, Jeffrey N., Murdoch, David M., Devinney, Michael J., Shaw, Leslie M., Cohen, Harvey Jay, Mathew, Joseph P., Akinyemi, Oladayo, Amundsen, Cindy, Avasarala, Pallavi, Barber, Matthew, Beach, Rachel, Berchuck, Andrew, Blazer, Dan G., Bolognesi, Michael, Brassard, Rachele, Bullock, W. Michael, Burke, Ashley, Cai, Victor, Cheong, Vanessa, Christensen, Soren, Cox, Mitchell, Crabtree, Donna, D'Amico, Thomas, Davidson, Brittany, Deorio, James, Easley, Mark E., Ehieli, Eric, Erdmann, Detlev, Funk, Bonita, Gadsden, Jeffrey, Garrigues, Grant, Greenup, Rachel, Habib, Ashraf, Harpole, David, Hartwig, Matthew, Havrilesky, Laura, Henley, Tarrah, Holland, Courtney, Hollenbeck, Scott, Huang, Richard, Iboaya, Ehimenem, Kawasaki, Amie, Klapper, Jacob, Knechtle, Stuart J., Lagoo‐Deenadayalan, Sandhya, Lee, Walter T., Lewis, Brian D., Lipkin, Michael, Litchfield, Heather, Marlor, Ellie, Maxwell, Cory, Migaly, John, Moul, Judd, Olson, Steven, Pappas, Theodore, Pellom, Gary Lee, Peterson, Andrew, Podgoreanu, Andreea, Polascik, Thomas, Preminger, Glenn, Previs, Rebecca, Rampersaud, Edward, Renne, Angela, Roman, Sanziana, Sanders, Edward, Sandler, Aaron, Scales, Charles, Seymour, Keri, Shah, Kevin N., Stang, Michael, Stanley, Samuel, Sweeney, Katherine, Szydlowska, Alicja, Terrando, Niccolo, Thacker, Julie, Thomas, Jake, Tong, Betty, Toulgoat‐DuBois, Yanne, Wellman, Samuel, Williams, David, Zani, Sabino, Enzor, Jennifer H., Staats, Janet

“…BACKGROUND/OBJECTIVES Every year, up to 40% of the more than 16 million older Americans who undergo anesthesia/surgery develop postoperative cognitive…”
Get full text

The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry by Armstrong, April W., Fitzgerald, Timothy, McLean, Robert R., Teeple, Amanda, Uy, Jonathan P., Olurinde, Mobolaji, Rowland, Katelyn, Guo, Lin, Shan, Ying, Callis Duffin, Kristina

“…Introduction Prior studies have demonstrated guselkumab improves disease activity and patient-reported outcomes (PROs) among patients with moderate-to-severe…”
Get full text

Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database by Fitzgerald, Timothy, Near, Aimee M., Kim, Hyunchung, Teeple, Amanda, Olurinde, Mobolaji, Rowland, Katelyn

“…Introduction Biologics have expanded the treatment options in the management of patients with moderate-to-severe psoriasis. The objective of this study was to…”
Get full text

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry by Armstrong, April W., Fitzgerald, Timothy, McLean, Robert R., Teeple, Amanda, Uy, Jonathan P., Olurinde, Mobolaji, Rowland, Katelyn, Guo, Lin, Shan, Ying, Callis Duffin, Kristina

“…Introduction In clinical trials, treatment with the interleukin-23 inhibitor guselkumab was associated with significantly improved disease severity and…”
Get full text

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry by Armstrong, April W., Fitzgerald, Timothy, McLean, Robert R., Teeple, Amanda, Uy, Jonathan P., Olurinde, Mobolaji, Rowland, Katelyn, Guo, Lin, Shan, Ying, Callis Duffin, Kristina

“…Introduction Guselkumab, an anti-interleukin-23 biologic therapy, has been shown to significantly reduce disease activity and improve patient-reported outcome…”
Get full text